Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Endothelin-1 Augments Therapeutic Potency of Human Mesenchymal Stem Cells via CDH2 and VEGF Signaling.

Lee EJ, Hwang I, Kim GH, Moon D, Kang SY, Hwang IC, Lee SY, Marie PJ, Kim HS.

Mol Ther Methods Clin Dev. 2019 May 17;13:503-511. doi: 10.1016/j.omtm.2019.05.003. eCollection 2019 Jun 14.

2.

Fibroblast growth factors in skeletal development.

Ornitz DM, Marie PJ.

Curr Top Dev Biol. 2019;133:195-234. doi: 10.1016/bs.ctdb.2018.11.020. Epub 2019 Jan 3.

PMID:
30902253
3.

Correction: Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells.

Mansouri R, Jouan Y, Hay E, Blin-Wakkach C, Frain M, Ostertag A, Le Henaff C, Marty C, Geoffroy V, Marie PJ, Cohen-Solal M, Modrowski D.

Cell Death Dis. 2018 Jul 16;9(8):788. doi: 10.1038/s41419-018-0830-4.

4.

The Expanding Life and Functions of Osteogenic Cells: From Simple Bone-Making Cells to Multifunctional Cells and Beyond.

Marie PJ, Cohen-Solal M.

J Bone Miner Res. 2018 Feb;33(2):199-210. doi: 10.1002/jbmr.3356. Epub 2018 Jan 16. Review.

5.

Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells.

Mansouri R, Jouan Y, Hay E, Blin-Wakkach C, Frain M, Ostertag A, Le Henaff C, Marty C, Geoffroy V, Marie PJ, Cohen-Solal M, Modrowski D.

Cell Death Dis. 2017 Jun 29;8(6):e2902. doi: 10.1038/cddis.2017.287. Erratum in: Cell Death Dis. 2018 Jul 16;9(8):788.

6.

New insights into bone marrow adipocytes: Report from the First European Meeting on Bone Marrow Adiposity (BMA 2015).

Hardouin P, Marie PJ, Rosen CJ.

Bone. 2016 Dec;93:212-215. doi: 10.1016/j.bone.2015.11.013. Epub 2015 Nov 30. No abstract available.

PMID:
26608519
7.

Genetic deletion of keratin 8 corrects the altered bone formation and osteopenia in a mouse model of cystic fibrosis.

Le Henaff C, Faria Da Cunha M, Hatton A, Tondelier D, Marty C, Collet C, Zarka M, Geoffroy V, Zatloukal K, Laplantine E, Edelman A, Sermet-Gaudelus I, Marie PJ.

Hum Mol Genet. 2016 Apr 1;25(7):1281-93. doi: 10.1093/hmg/ddw009. Epub 2016 Jan 13.

PMID:
26769674
8.

Periosteum Metabolism and Nerve Fiber Positioning Depend on Interactions between Osteoblasts and Peripheral Innervation in Rat Mandible.

Mauprivez C, Bataille C, Baroukh B, Llorens A, Lesieur J, Marie PJ, Saffar JL, Biosse Duplan M, Cherruau M.

PLoS One. 2015 Oct 28;10(10):e0140848. doi: 10.1371/journal.pone.0140848. eCollection 2015.

9.

Fibroblast growth factor signaling in skeletal development and disease.

Ornitz DM, Marie PJ.

Genes Dev. 2015 Jul 15;29(14):1463-86. doi: 10.1101/gad.266551.115. Review.

10.

Increased NF-κB Activity and Decreased Wnt/β-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice.

Le Henaff C, Mansouri R, Modrowski D, Zarka M, Geoffroy V, Marty C, Tarantino N, Laplantine E, Marie PJ.

J Biol Chem. 2015 Jul 17;290(29):18009-17. doi: 10.1074/jbc.M115.646208. Epub 2015 Jun 9.

11.

Role of syndecan-2 in osteoblast biology and pathology.

Mansouri R, Haÿ E, Marie PJ, Modrowski D.

Bonekey Rep. 2015 Apr 1;4:666. doi: 10.1038/bonekey.2015.33. eCollection 2015. Review.

12.

Wnt/β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells.

Saidak Z, Le Henaff C, Azzi S, Marty C, Da Nascimento S, Sonnet P, Marie PJ.

J Biol Chem. 2015 Mar 13;290(11):6903-12. doi: 10.1074/jbc.M114.621219. Epub 2015 Jan 28.

13.

Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Marie PJ.

Cell Mol Life Sci. 2015 Apr;72(7):1347-61. doi: 10.1007/s00018-014-1801-2. Epub 2014 Dec 9. Review.

PMID:
25487608
14.

Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.

Saidak Z, Le Henaff C, Azzi S, Marty C, Marie PJ.

J Endocrinol. 2014 Oct;223(1):25-33. doi: 10.1530/JOE-14-0249. Epub 2014 Jul 23.

PMID:
25056116
15.

Integrin and cadherin signaling in bone: role and potential therapeutic targets.

Marie PJ, Haÿ E, Saidak Z.

Trends Endocrinol Metab. 2014 Nov;25(11):567-75. doi: 10.1016/j.tem.2014.06.009. Epub 2014 Jul 14. Review.

PMID:
25034128
16.

N-cadherin/wnt interaction controls bone marrow mesenchymal cell fate and bone mass during aging.

Haÿ E, Dieudonné FX, Saidak Z, Marty C, Brun J, Da Nascimento S, Sonnet P, Marie PJ.

J Cell Physiol. 2014 Nov;229(11):1765-75. doi: 10.1002/jcp.24629.

PMID:
24664975
17.

Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis.

Le Henaff C, Haÿ E, Velard F, Marty C, Tabary O, Marie PJ, Jacquot JP.

Am J Pathol. 2014 Apr;184(4):1132-1141. doi: 10.1016/j.ajpath.2013.12.027. Epub 2014 Feb 11.

PMID:
24529904
18.

Bone cell senescence: mechanisms and perspectives.

Marie PJ.

J Bone Miner Res. 2014 Jun;29(6):1311-21. doi: 10.1002/jbmr.2190. Review.

19.

Cadherins and Wnt signalling: a functional link controlling bone formation.

Marie PJ, Haÿ E.

Bonekey Rep. 2013 Apr 17;2:330. doi: 10.1038/bonekey.2013.64.

20.

Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.

Habel N, Hamidouche Z, Girault I, Patiño-García A, Lecanda F, Marie PJ, Fromigué O.

Cell Death Dis. 2013 Oct 24;4:e874. doi: 10.1038/cddis.2013.405.

21.

Cadherin-mediated cell-cell adhesion and signaling in the skeleton.

Marie PJ, Haÿ E, Modrowski D, Revollo L, Mbalaviele G, Civitelli R.

Calcif Tissue Int. 2014 Jan;94(1):46-54. doi: 10.1007/s00223-013-9733-7. Epub 2013 May 9. Review.

22.

ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo.

Jullien N, Dieudonné FX, Habel N, Marty C, Modrowski D, Patino A, Lecanda F, Sévère N, Marie PJ.

Gene. 2013 May 25;521(1):55-61. doi: 10.1016/j.gene.2013.03.031. Epub 2013 Mar 27.

PMID:
23541807
23.

Promotion of osteoblast differentiation in mesenchymal cells through Cbl-mediated control of STAT5 activity.

Dieudonne FX, Sévère N, Biosse-Duplan M, Weng JJ, Su Y, Marie PJ.

Stem Cells. 2013 Jul;31(7):1340-9. doi: 10.1002/stem.1380.

24.

FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo.

Brun J, Dieudonné FX, Marty C, Müller J, Schüle R, Patiño-García A, Lecanda F, Fromigué O, Marie PJ.

PLoS One. 2013;8(1):e55034. doi: 10.1371/journal.pone.0055034. Epub 2013 Jan 28.

25.

Targeting integrins to promote bone formation and repair.

Marie PJ.

Nat Rev Endocrinol. 2013 May;9(5):288-95. doi: 10.1038/nrendo.2013.4. Epub 2013 Jan 29. Review.

PMID:
23358353
26.

E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.

Sévère N, Dieudonné FX, Marie PJ.

Cell Death Dis. 2013 Jan 17;4:e463. doi: 10.1038/cddis.2012.217. Review.

27.

The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b.

Brun J, Fromigué O, Dieudonné FX, Marty C, Chen J, Dahan J, Wei Y, Marie PJ.

Bone. 2013 Mar;53(1):6-12. doi: 10.1016/j.bone.2012.11.020. Epub 2012 Nov 29.

PMID:
23201222
28.

Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis.

Saidak Z, Marie PJ.

Pharmacol Ther. 2012 Nov;136(2):216-26. doi: 10.1016/j.pharmthera.2012.07.009. Epub 2012 Jul 20. Review.

PMID:
22820094
29.

Signaling pathways affecting skeletal health.

Marie PJ.

Curr Osteoporos Rep. 2012 Sep;10(3):190-8. doi: 10.1007/s11914-012-0109-0. Review.

PMID:
22711369
30.

Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.

Sévère N, Dieudonné FX, Marty C, Modrowski D, Patiño-García A, Lecanda F, Fromigué O, Marie PJ.

J Bone Miner Res. 2012 Oct;27(10):2108-17. doi: 10.1002/jbmr.1667.

31.

Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.

Haÿ E, Buczkowski T, Marty C, Da Nascimento S, Sonnet P, Marie PJ.

J Bone Miner Res. 2012 Sep;27(9):1852-63. doi: 10.1002/jbmr.1656.

32.

Peptide-based activation of alpha5 integrin for promoting osteogenesis.

Fromigué O, Brun J, Marty C, Da Nascimento S, Sonnet P, Marie PJ.

J Cell Biochem. 2012 Sep;113(9):3029-38. doi: 10.1002/jcb.24181.

PMID:
22566152
33.

Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.

Dieudonné FX, Marion A, Marie PJ, Modrowski D.

J Bone Miner Res. 2012 Oct;27(10):2118-29. doi: 10.1002/jbmr.1650.

34.

Fibroblast growth factor signaling controlling bone formation: an update.

Marie PJ.

Gene. 2012 Apr 25;498(1):1-4. doi: 10.1016/j.gene.2012.01.086. Epub 2012 Feb 9. Review.

PMID:
22342254
35.

Different sympathetic pathways control the metabolism of distinct bone envelopes.

Bataille C, Mauprivez C, Haÿ E, Baroukh B, Brun A, Chaussain C, Marie PJ, Saffar JL, Cherruau M.

Bone. 2012 May;50(5):1162-72. doi: 10.1016/j.bone.2012.01.023. Epub 2012 Feb 2.

PMID:
22326888
36.

Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling.

Saidak Z, Haÿ E, Marty C, Barbara A, Marie PJ.

Aging Cell. 2012 Jun;11(3):467-74. doi: 10.1111/j.1474-9726.2012.00804.x. Epub 2012 Mar 12.

37.

FGF/FGFR signaling in bone formation: progress and perspectives.

Marie PJ, Miraoui H, Sévère N.

Growth Factors. 2012 Apr;30(2):117-23. doi: 10.3109/08977194.2012.656761. Epub 2012 Feb 1. Review.

PMID:
22292523
38.

Downregulation of ErbB3 by Wnt3a contributes to wnt-induced osteoblast differentiation in mesenchymal cells.

Jullien N, Maudinet A, Leloutre B, Ringe J, Häupl T, Marie PJ.

J Cell Biochem. 2012 Jun;113(6):2047-56. doi: 10.1002/jcb.24076.

PMID:
22274864
39.

Lentiviral-mediated integrin α5 expression in human adult mesenchymal stromal cells promotes bone repair in mouse cranial and long-bone defects.

Srouji S, Ben-David D, Fromigué O, Vaudin P, Kuhn G, Müller R, Livne E, Marie PJ.

Hum Gene Ther. 2012 Feb;23(2):167-72. doi: 10.1089/hum.2011.059. Epub 2011 Dec 2.

PMID:
21958321
40.

Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.

Marion A, Dieudonné FX, Patiño-Garcia A, Lecanda F, Marie PJ, Modrowski D.

Int J Cancer. 2012 Jun 1;130(11):2514-25. doi: 10.1002/ijc.26246. Epub 2011 Aug 16.

42.

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.

Marie PJ, Kassem M.

Eur J Endocrinol. 2011 Jul;165(1):1-10. doi: 10.1530/EJE-11-0132. Epub 2011 May 4. Review.

PMID:
21543379
43.

Functional relevance of the BMD-associated polymorphism rs312009: novel involvement of RUNX2 in LRP5 transcriptional regulation.

Agueda L, Velázquez-Cruz R, Urreizti R, Yoskovitz G, Sarrión P, Jurado S, Güerri R, Garcia-Giralt N, Nogués X, Mellibovsky L, Díez-Pérez A, Marie PJ, Balcells S, Grinberg D.

J Bone Miner Res. 2011 May;26(5):1133-44. doi: 10.1002/jbmr.293.

44.

Cell and gene therapy for bone repair.

Marie PJ.

Osteoporos Int. 2011 Jun;22(6):2023-6. doi: 10.1007/s00198-011-1615-0. Review.

PMID:
21523396
45.

CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.

Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B, Marie PJ.

J Bone Miner Res. 2011 Jul;26(7):1533-42. doi: 10.1002/jbmr.343.

46.

Senescence-associated intrinsic mechanisms of osteoblast dysfunctions.

Kassem M, Marie PJ.

Aging Cell. 2011 Apr;10(2):191-7. doi: 10.1111/j.1474-9726.2011.00669.x. Epub 2011 Feb 18. Review.

47.

Extrinsic mechanisms involved in age-related defective bone formation.

Marie PJ, Kassem M.

J Clin Endocrinol Metab. 2011 Mar;96(3):600-9. doi: 10.1210/jc.2010-2113. Epub 2011 Jan 5. Review.

PMID:
21209032
48.

[CT scan, MR imaging and anatomopathologic correlation in the glottic carcinoma T1-T2].

Bertrand M, Tollard E, François A, Bouchetetemble P, Marie PJ, Dehesdin D, Choussy O.

Rev Laryngol Otol Rhinol (Bord). 2010;131(1):51-7. French.

PMID:
21086659
49.

Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology.

Marie PJ.

Mol Interv. 2010 Oct;10(5):305-12. doi: 10.1124/mi.10.5.7. Review.

PMID:
21045244
50.

Fibroblast growth factor receptor signaling crosstalk in skeletogenesis.

Miraoui H, Marie PJ.

Sci Signal. 2010 Nov 2;3(146):re9. doi: 10.1126/scisignal.3146re9. Review.

PMID:
21045207

Supplemental Content

Loading ...
Support Center